Quick Answer
Esperion Therapeutics, Inc. reported Total Revenue of $403.13 million for fiscal year 2025.
Esperion Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $403.13M +21.3% |
$332.31M +185.7% |
$116.33M +54.1% |
$75.47M -3.8% |
$78.45M -65.5% |
$227.55M +53.4% |
| Revenue (ASC 606) | $403.13M +21.3% |
$332.31M +185.7% |
$116.33M +54.1% |
$75.47M -3.8% |
$78.45M -65.5% |
$227.55M +53.4% |
| Net Income | -$22.68M +56.2% |
-$51.74M +75.3% |
-$209.25M +10.4% |
-$233.66M +13.2% |
-$269.11M -87.5% |
-$143.55M -47.7% |
| Diluted EPS | -$0.11 +60.7% |
-$0.28 +86.2% |
-$2.03 +42.3% |
-$3.52 +62.2% |
-$9.31 -78.0% |
-$5.23 -45.7% |
| Total Assets | $465.89M +35.5% |
$343.82M +67.1% |
$205.80M -17.0% |
$247.94M -35.0% |
$381.59M +8.0% |
$353.26M +64.7% |
| Cash and Equivalents | $167.85M +16.0% |
$144.76M +76.0% |
$82.25M -34.1% |
$124.78M -40.3% |
$208.89M -31.5% |
$304.96M +83.6% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | -$301.96M +22.3% |
-$388.72M +14.6% |
-$454.99M -40.5% |
-$323.78M -64.4% |
-$196.94M -104.9% |
-$96.13M -581.9% |
| Operating Income | $60.27M +10.8% |
$54.40M +135.0% |
-$155.56M +13.3% |
-$179.50M +20.8% |
-$226.73M -86.8% |
-$121.40M -30.4% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $87.31M | +69.1% | +6.0% |
| Revenue (ASC 606) | September 30, 2025 | $87.31M | +69.1% | +6.0% |
| Net Income | September 30, 2025 | -$31.33M | -6.1% | -146.2% |
| Diluted EPS | September 30, 2025 | -$0.16 | -6.7% | -166.7% |
| Total Assets | September 30, 2025 | $364.02M | +15.9% | +4.9% |
| Cash and Equivalents | September 30, 2025 | $92.45M | -36.1% | +7.4% |
| Long-Term Debt | June 30, 2017 | $140.0K | -92.5% | -76.1% |
| Stockholders Equity | September 30, 2025 | -$451.36M | -21.9% | -4.1% |
| Operating Income | September 30, 2025 | -$9.96M | +37.9% | -240.4% |
| Shares Outstanding | September 30, 2020 | 27.86M | +2.5% | +0.4% |
- Esperion Therapeutics, Inc. reported Total Revenue of $403.13 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +21.3% in Total Revenue compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Revenue (ASC 606) of $403.13 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +21.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Net Income of -$22.68 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +56.2% in Net Income compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Diluted EPS of $0.11 per share (loss) for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +60.7% in Diluted EPS compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Total Assets of $465.89 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +35.5% in Total Assets compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Cash and Equivalents of $167.85 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +16.0% in Cash and Equivalents compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Long-Term Debt of $1.02 million for fiscal year 2016.
- Esperion Therapeutics, Inc. showed a decrease of -62.0% in Long-Term Debt compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Stockholders Equity of -$301.96 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +22.3% in Stockholders Equity compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Operating Income of $60.27 million for fiscal year 2025.
- Esperion Therapeutics, Inc. showed an increase of +10.8% in Operating Income compared to the prior fiscal year.
- Esperion Therapeutics, Inc. reported Shares Outstanding of 27.50 million shares for fiscal year 2019.
- Esperion Therapeutics, Inc. showed an increase of +2.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: